BiotechTube

Isavuconazole

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Invasive Aspergillosis

Conditions

Invasive Aspergillosis, Mucormycosis

Trial Timeline

Mar 10, 2021 → Dec 23, 2023

NCT ID
NCT04550936

About Isavuconazole

Isavuconazole is a pre-clinical stage product being developed by Pfizer for Invasive Aspergillosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04550936. Target conditions include Invasive Aspergillosis, Mucormycosis.

What happened to similar drugs?

4 of 20 similar drugs in Invasive Aspergillosis were approved

Approved (4) Terminated (2) Active (15)
🔄Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
🔄Micafungin + fluconazoleAstellas PharmaPhase 3
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
❌Micafungin + PlaceboAstellas PharmaPhase 3
✅MicafunginAstellas PharmaApproved
🔄Olorofim + AmBisome®ShionogiPhase 3
🔄Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05630976ApprovedCompleted
NCT04550936Pre-clinicalCompleted

Competing Products

20 competing products in Invasive Aspergillosis

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
39
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Trastuzumab deruxtecan + DurvalumabDaiichi SankyoPhase 2
42
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPre-clinical
26
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Pudexacianinium chlorideAstellas PharmaPhase 2
35
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
26
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Isavuconazonium sulfate + Isavuconazonium sulfateAstellas PharmaPhase 2
35
Micafungin + Systemic antifungal therapyAstellas PharmaPhase 2
27
MicafunginAstellas PharmaPre-clinical
26
Micafungin + PlaceboAstellas PharmaPhase 3
32
MicafunginAstellas PharmaApproved
35
Olorofim + AmBisome®ShionogiPhase 3
44
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
44
SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3
47